PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST)
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
PRELUDE THERAPEUTICS INC
NASDAQ:PRLD (2/11/2025, 3:32:34 PM)
0.94
-0.15 (-13.76%)
PRLD Latest News and Analysis
a day ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
